• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微管蛋白结合剂急性效应的非侵入性评估:肿瘤血管破坏成像综述

Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

作者信息

Liu Li, O'Kelly Devin, Schuetze Regan, Carlson Graham, Zhou Heling, Trawick Mary Lynn, Pinney Kevin G, Mason Ralph P

机构信息

Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Department of Chemistry and Biochemistry, Baylor University, Waco, TX 76798, USA.

出版信息

Molecules. 2021 Apr 27;26(9):2551. doi: 10.3390/molecules26092551.

DOI:10.3390/molecules26092551
PMID:33925707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8125421/
Abstract

Tumor vasculature proliferates rapidly, generally lacks pericyte coverage, and is uniquely fragile making it an attractive therapeutic target. A subset of small-molecule tubulin binding agents cause disaggregation of the endothelial cytoskeleton leading to enhanced vascular permeability generating increased interstitial pressure. The resulting vascular collapse and ischemia cause downstream hypoxia, ultimately leading to cell death and necrosis. Thus, local damage generates massive amplification and tumor destruction. The tumor vasculature is readily accessed and potentially a common target irrespective of disease site in the body. Development of a therapeutic approach and particularly next generation agents benefits from effective non-invasive assays. Imaging technologies offer varying degrees of sophistication and ease of implementation. This review considers technological strengths and weaknesses with examples from our own laboratory. Methods reveal vascular extent and patency, as well as insights into tissue viability, proliferation and necrosis. Spatiotemporal resolution ranges from cellular microscopy to single slice tomography and full three-dimensional views of whole tumors and measurements can be sufficiently rapid to reveal acute changes or long-term outcomes. Since imaging is non-invasive, each tumor may serve as its own control making investigations particularly efficient and rigorous. The concept of tumor vascular disruption was proposed over 30 years ago and it remains an active area of research.

摘要

肿瘤血管迅速增殖,通常缺乏周细胞覆盖,且异常脆弱,这使其成为一个有吸引力的治疗靶点。一部分小分子微管蛋白结合剂会导致内皮细胞骨架解聚,从而增强血管通透性,使组织间隙压力升高。由此导致的血管塌陷和缺血会引起下游缺氧,最终导致细胞死亡和坏死。因此,局部损伤会引发大规模放大效应并导致肿瘤破坏。肿瘤血管易于触及,并且可能是一个通用靶点,而与身体中的疾病部位无关。开发一种治疗方法,尤其是新一代药物,受益于有效的非侵入性检测。成像技术的复杂程度和实施难度各不相同。本综述结合我们自己实验室的实例,探讨了这些技术的优缺点。这些方法可以揭示血管范围和通畅情况,以及对组织活力、增殖和坏死的洞察。时空分辨率范围从细胞显微镜检查到单层断层扫描,再到整个肿瘤的完整三维视图,测量速度足够快,可以揭示急性变化或长期结果。由于成像是非侵入性的,每个肿瘤都可以作为自身的对照,这使得研究特别高效和严谨。肿瘤血管破坏的概念在30多年前就已提出,它仍然是一个活跃的研究领域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/fbfcd98ab14d/molecules-26-02551-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/1783cfcab281/molecules-26-02551-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/e052a6aec800/molecules-26-02551-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/fe45d1863c2e/molecules-26-02551-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/da8123c12981/molecules-26-02551-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/25b7326dc5df/molecules-26-02551-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/f199ce5e309d/molecules-26-02551-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/d103c0c4c5c6/molecules-26-02551-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/a595cae428c1/molecules-26-02551-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/2adc796cd970/molecules-26-02551-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/47cb8f54bd1d/molecules-26-02551-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/fbfcd98ab14d/molecules-26-02551-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/1783cfcab281/molecules-26-02551-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/e052a6aec800/molecules-26-02551-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/fe45d1863c2e/molecules-26-02551-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/da8123c12981/molecules-26-02551-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/25b7326dc5df/molecules-26-02551-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/f199ce5e309d/molecules-26-02551-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/d103c0c4c5c6/molecules-26-02551-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/a595cae428c1/molecules-26-02551-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/2adc796cd970/molecules-26-02551-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/47cb8f54bd1d/molecules-26-02551-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ee/8125421/fbfcd98ab14d/molecules-26-02551-g011.jpg

相似文献

1
Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.微管蛋白结合剂急性效应的非侵入性评估:肿瘤血管破坏成像综述
Molecules. 2021 Apr 27;26(9):2551. doi: 10.3390/molecules26092551.
2
A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.一种与微管蛋白相互作用的血管破坏剂的观点:临床前肿瘤成像和生物学评估。
Integr Biol (Camb). 2011 Apr;3(4):375-87. doi: 10.1039/c0ib00135j. Epub 2011 Feb 14.
3
BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy.BNC105:一种新型的微管聚合抑制剂,能选择性地破坏肿瘤血管,并具有单药抗肿瘤疗效。
Mol Cancer Ther. 2010 Jun;9(6):1562-73. doi: 10.1158/1535-7163.MCT-09-0815. Epub 2010 Jun 1.
4
Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.CKD-516 的血管破坏作用:使用 DCE-MRI 的临床前研究。
Invest New Drugs. 2013 Oct;31(5):1097-106. doi: 10.1007/s10637-012-9915-6. Epub 2013 Jan 9.
5
Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.作为处于临床开发阶段的血管破坏剂的微管蛋白秋水仙碱结合位点抑制剂。
Curr Med Chem. 2015;22(11):1348-60. doi: 10.2174/0929867322666150114163732.
6
Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis.微管蛋白抑制剂在纳米颗粒药物递送及血管破坏/血管生成方面的研究进展
Molecules. 2016 Nov 2;21(11):1468. doi: 10.3390/molecules21111468.
7
Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.通过使微管蛋白不稳定来阻断实体瘤的血流:一种靶向肿瘤生长的方法。
J Med Chem. 2016 Oct 13;59(19):8685-8711. doi: 10.1021/acs.jmedchem.6b00463. Epub 2016 Jun 27.
8
Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.微管蛋白结合查耳酮TUB091的抗血管生成和抗肿瘤特性
Oncotarget. 2017 Feb 28;8(9):14325-14342. doi: 10.18632/oncotarget.9527.
9
Vascular disrupting agents in clinical development.处于临床开发阶段的血管破坏剂
Br J Cancer. 2007 Apr 23;96(8):1159-65. doi: 10.1038/sj.bjc.6603694. Epub 2007 Mar 20.
10
Combination of vascular disrupting agents and ionizing radiation.联合血管破坏剂和电离辐射。
Crit Rev Oncol Hematol. 2013 May;86(2):143-60. doi: 10.1016/j.critrevonc.2012.10.002. Epub 2012 Nov 20.

引用本文的文献

1
Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization.苯并环庚烯及其四环类似物作为微管蛋白聚合的秋水仙碱位点抑制剂。
ACS Med Chem Lett. 2025 May 26;16(6):1098-1107. doi: 10.1021/acsmedchemlett.5c00129. eCollection 2025 Jun 12.
2
Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice.评估血管破坏剂OXi8007对小鼠肾癌的治疗效果。
Cancers (Basel). 2025 Feb 24;17(5):771. doi: 10.3390/cancers17050771.
3
Macrocarpal I induces immunogenic cell death and synergizes with immune checkpoint inhibition by targeting tubulin and PARP1 in colorectal cancer.

本文引用的文献

1
Tumor Neovasculature-Targeted APRPG-PEG-PDLLA/MPEG-PDLLA Mixed Micelle Loading Combretastatin A-4 for Breast Cancer Therapy.肿瘤新生血管靶向的载有康普瑞汀A-4的APRPG-PEG-PDLLA/MPEG-PDLLA混合胶束用于乳腺癌治疗
ACS Biomater Sci Eng. 2018 Jun 11;4(6):1986-1999. doi: 10.1021/acsbiomaterials.7b00523. Epub 2017 Sep 21.
2
Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.多平台成像在癌症动物模型中的临床前应用
Cancer Res. 2021 Mar 1;81(5):1189-1200. doi: 10.1158/0008-5472.CAN-20-0373. Epub 2020 Dec 1.
3
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
大果紫檀素I通过靶向微管蛋白和PARP1在结直肠癌中诱导免疫原性细胞死亡并与免疫检查点抑制协同作用。
Cell Death Discov. 2025 Feb 22;11(1):73. doi: 10.1038/s41420-025-02360-9.
4
Drug-Linker Constructs Bearing Unique Dual-Mechanism Tubulin Binding Payloads Tethered through Cleavable and Non-Cleavable Linkers.通过可裂解和不可裂解连接子连接的具有独特双机制微管蛋白结合有效载荷的药物-连接子构建体。
Tetrahedron. 2025 Feb 1;171. doi: 10.1016/j.tet.2024.134350. Epub 2024 Nov 6.
5
Design, Synthesis and Biological Evaluation of 2-Phenyl Indole Analogues of OXi8006 as Colchicine Site Inhibitors of Tubulin Polymerization and Vascular Disrupting Agents.作为微管蛋白聚合的秋水仙碱位点抑制剂和血管破坏剂的OXi8006的2-苯基吲哚类似物的设计、合成及生物学评价
Bioorg Med Chem. 2025 Feb 1;118:117981. doi: 10.1016/j.bmc.2024.117981. Epub 2024 Nov 7.
6
Application of Chlorosulfonyl Isocyanate (CSI) in the Synthesis of Fused Tetracyclic Ketone Ring Systems.氯磺酰异氰酸酯(CSI)在稠合四环酮环体系合成中的应用。
J Org Chem. 2024 Nov 1;89(21):15636-15651. doi: 10.1021/acs.joc.4c01714. Epub 2024 Oct 10.
7
Innovative Imaging Techniques for Advancing Cancer Diagnosis and Treatment.推进癌症诊断与治疗的创新成像技术
Cancers (Basel). 2024 Jul 22;16(14):2607. doi: 10.3390/cancers16142607.
8
Super-Resolution Ultrasound Imaging for Monitoring the Therapeutic Efficacy of a Vascular Disrupting Agent in an Animal Model of Breast Cancer.超声超分辨率成像监测血管破坏剂在乳腺癌动物模型中的治疗效果。
J Ultrasound Med. 2024 Jun;43(6):1099-1107. doi: 10.1002/jum.16438. Epub 2024 Feb 27.
9
Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization.合成及结构多样的 6-芳基-3-酰基吲哚类似物作为微管蛋白聚合抑制剂的生物评价。
Eur J Med Chem. 2024 Jan 5;263:115794. doi: 10.1016/j.ejmech.2023.115794. Epub 2023 Sep 6.
10
Structure Guided Design, Synthesis, and Biological Evaluation of Oxetane-Containing Indole Analogues.基于结构导向设计的含环氧乙烷吲哚类似物的合成与生物评价。
Bioorg Med Chem. 2023 Sep 7;92:117400. doi: 10.1016/j.bmc.2023.117400. Epub 2023 Jun 29.
CKD-516 联合放疗在肺鳞癌异种移植小鼠模型中的抗肿瘤疗效。
BMC Cancer. 2020 Nov 3;20(1):1057. doi: 10.1186/s12885-020-07566-x.
4
Vascular disrupting agents in cancer therapy.血管破坏剂在癌症治疗中的应用。
Eur J Pharmacol. 2021 Jan 15;891:173692. doi: 10.1016/j.ejphar.2020.173692. Epub 2020 Oct 29.
5
High Sensitivity In Vivo Imaging of Cancer Metastasis Using a Near-Infrared Luciferin Analogue seMpai.利用近红外萤光素类似物 seMpai 进行体内高灵敏度癌症转移成像
Int J Mol Sci. 2020 Oct 24;21(21):7896. doi: 10.3390/ijms21217896.
6
Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration.经肝动脉注射血管破坏剂治疗的兔 VX2 肝肿瘤的影像学-组织病理学相关性。
Int J Med Sci. 2020 Aug 25;17(15):2269-2275. doi: 10.7150/ijms.46165. eCollection 2020.
7
Use of photoacoustic imaging for monitoring vascular disrupting cancer treatments.光声成像在监测血管破坏型癌症治疗中的应用。
J Biophotonics. 2023 Apr;16(4):e202000209. doi: 10.1002/jbio.202000209. Epub 2020 Sep 14.
8
Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.在一项抗癌血管破坏剂克罗利布林的 1 期临床研究中,通过定量 MRI 进行剂量反应评估。
Sci Rep. 2020 Sep 2;10(1):14449. doi: 10.1038/s41598-020-71246-w.
9
Bioluminescence Imaging Applications in Cancer: A Comprehensive Review.生物发光成像在癌症中的应用:全面综述。
IEEE Rev Biomed Eng. 2021;14:307-326. doi: 10.1109/RBME.2020.2995124. Epub 2021 Jan 22.
10
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.贝伐珠单抗联合福司替尼治疗复发性卵巢癌:NRG 肿瘤学/妇科肿瘤学组的一项随机 II 期研究的总生存期和探索性分析。
Gynecol Oncol. 2020 Oct;159(1):79-87. doi: 10.1016/j.ygyno.2020.07.015. Epub 2020 Jul 26.